GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Insider Ownership

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Insider Ownership : 36.62 % (As of May. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Merrimack Pharmaceuticals's insider ownership is 36.62%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Merrimack Pharmaceuticals's Institutional Ownership is 18.59%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Merrimack Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 70.29%.


Merrimack Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Merrimack Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Insider Ownership Chart

Merrimack Pharmaceuticals Historical Data

The historical data trend for Merrimack Pharmaceuticals can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Insider Ownership 37.16 37.16 37.16 37.16 37.16 37.16 37.16 37.16 36.62 36.62

Merrimack Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
One Broadway, 14th Floor, Cambridge, MA, USA, 02142
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.
Executives
Eric Andersen director, other: See Remarks 1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker director, officer: President MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy director, other: See Remarks 60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic director 2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen director MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray director 2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p. other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp other: See Remarks 5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc other: See Remarks 5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc other: See Remarks 60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc. 10 percent owner, other: See Explanation of Responses 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Headlines

From GuruFocus

Merrimack Reports Second Quarter 2022 Financial Results

By Business Wire Business Wire 08-04-2022

Merrimack Declares $20 Million Special Dividend

By PRNewswire PRNewswire 07-25-2019

JFL Capital Issues Letter to Fellow Merrimack Stockholders

By PRNewswire PRNewswire 08-22-2019

Merrimack Discontinues Development of MM-310

By PRNewswire PRNewswire 04-05-2019

Merrimack Reports Full Year 2020 Financial Results

By Business Wire Business Wire 03-11-2021

Merrimack Reports First Quarter 2020 Financial Results

By Business Wire Business Wire 05-08-2020

Merrimack Reports Second Quarter 2021 Financial Results

By Business Wire Business Wire 08-05-2021